CliffBio
small molecule

DEFLAZACORT

DEFLAZACORT

Loss of exclusivity—loss of exclusivity
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameDEFLAZACORT
Active ingredientDEFLAZACORT
Strength22.75MG/ML
Dosage formSUSPENSION
RouteORAL
ModalitySmall molecule
FDA approvalApril 2024
Marketing statusRX

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DEFLAZACORT patent cliff — loss of exclusivity — | CliffBio